Psoriatic Arthritis | Disease Landscape and Forecast | G7 | 2016
PsA, a disease hallmarked by flaky psoriatic skin lesions, erosive joint damage, and complicating comorbidities, remains poorly understood, underdiagnosed, and undertreated. Nevertheless, TNF-α inhibitors have revolutionized treatment of the disease and expanded the PsA therapy market to a multibillion-dollar entity. In recent years, several novel therapies with alternative MOAs, such as the IL-12/23 inhibitor ustekinumab, the oral PDE-4 inhibitor apremilast, and the IL-17A inhibitor secukinumab, have entered this market and notably improved the outcome of patients who develop inadequate response to TNF-α inhibitors.
Currently, three biologics and one oral agent are in Phase III development for PsA and are expected to launch during the 2015-2025 study period. Thought-leading physicians describe a dynamic patient-management environment with a growing need for additional novel therapies. In this content, we analyze physician perception and anticipated positioning of these agents and the implications for the market-leading TNF-α inhibitor class.
